EBN resources page
SIGN Apps for iPhone and iPad
The SIGN app has recently been updated and now contains quick reference guides (QRGs) for:
SIGN 136 Management of chronic pain
SIGN 135 Management of epithelial ovarian cancer
SIGN 134 Treatment of primary breast cancer
SIGN 133 Management of hepatitis C
The SIGN app has also had a complete re-design and now features:
Optimisation for the latest operating systems
Re-designed for improved legibility
Send pdf button feature
Split screen feature (ipad)
Prevention of stroke in patients with atrial fibrillation: a guide for primary care
This guide summarises the current evidence available to support the management of atrial fibrillation in primary care. The guide was developed by Healthcare Improvement Scotland by collating existing recent advice and guidance, including evidence-based guidelines and consensus recommendations for practice in NHS Scotland.
SIGN 137: management of lung cancer
This guideline replaces SIGN 80. It covers all aspects of the management of patients with small-cell lung cancer and non-small cell lung cancer, and reflects the most recent evidence on diagnostic and staging investigations, surgery, radiotherapy and systemic anticancer therapy.
Cochrane Nursing Care Field Trials Register
The Cochrane Nursing Care Field Trials Register contains randomised controlled trials and other relevant trial reports. The studies considered relate to interventions that are considered to be integral to, or associated with, the delivery of nursing care and delivered across a wide range of specialties and settings.
Drug and Therapeutics Bulletin (DTB): September 2013—January 2014
Dapagliflozin (Forxiga) for type 2 diabetes?
Dapagliflozin belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria. It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control. The company’s advertising materials claim that dapagliflozin provides a ‘novel method of controlling excess glucose’ with ‘secondary benefit of weight …